Entry - #256810 - MITOCHONDRIAL DNA DEPLETION SYNDROME 6 (HEPATOCEREBRAL TYPE); MTDPS6 - OMIM

# 256810

MITOCHONDRIAL DNA DEPLETION SYNDROME 6 (HEPATOCEREBRAL TYPE); MTDPS6


Alternative titles; symbols

NAVAJO NEUROHEPATOPATHY; NNH
NAVAJO NEUROPATHY; NN


Other entities represented in this entry:

NAVAJO FAMILIAL NEUROGENIC ARTHROPATHY, INCLUDED

Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
2p23.3 Mitochondrial DNA depletion syndrome 6 (hepatocerebral type) 256810 AR 3 MPV17 137960
Clinical Synopsis
 
Phenotypic Series
 

INHERITANCE
- Autosomal recessive
GROWTH
Height
- Short stature
Weight
- Poor weight gain
Other
- Failure to thrive
HEAD & NECK
Eyes
- Corneal ulcerations
- Nystagmus
ABDOMEN
Liver
- Hepatomegaly
- Acute hepatic failure
- Reye syndrome-like episodes
- Biopsy shows multinucleated giant cells
- Macrovesicular steatosis
- Microvesicular steatosis
- Pseudo-acini
- Inflammation
- Cholestasis
- Bridging fibrosis
- Cirrhosis
- Mitochondrial DNA depletion in liver tissue
Gastrointestinal
- Vomiting
- Diarrhea
SKELETAL
- Painless fractures due to injury
Hands
- Acral ulceration and osteomyelitis leading to autoamputation
Feet
- Acral ulceration and osteomyelitis leading to autoamputation
SKIN, NAILS, & HAIR
Skin
- Neonatal jaundice
NEUROLOGIC
Central Nervous System
- Progressive white matter lesions in the brain
- Hypotonia
- Dystonia
- Ataxia
- Developmental delay
Peripheral Nervous System
- Progressive sensorimotor neuropathy
- Pain insensitivity
- Hyporeflexia
- Areflexia
- Muscle weakness, distal
- Delayed motor nerve conduction velocities (NCV)
- Loss of large and small myelinated fibers seen on nerve biopsy
METABOLIC FEATURES
- Lactic acidosis
- Hypoglycemia
IMMUNOLOGY
- Systemic infections
LABORATORY ABNORMALITIES
- Elevated liver enzymes
- Increased total and conjugated bilirubin
MISCELLANEOUS
- Early onset (1 month to 4 years)
- Frequently occurs in Navajo children, especially in Western reservations
- Death in the first decade, usually from liver failure
- Liver disease may be the most predominant finding
- Progressive disorder
- Phenotypic variability
MOLECULAR BASIS
- Caused by mutation in the mitochondrial inner membrane protein MPV17 gene (MPV17, 137960.0001)
Mitochondrial DNA depletion syndrome - PS603041 - 25 Entries
Location Phenotype Inheritance Phenotype
mapping key
Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
1q42.13 Mitochondrial DNA depletion syndrome 21 AR 3 621071 GUK1 139270
2p23.3 Mitochondrial DNA depletion syndrome 6 (hepatocerebral type) AR 3 256810 MPV17 137960
2p13.1 Mitochondrial DNA depletion syndrome 3 (hepatocerebral type) AR 3 251880 DGUOK 601465
2p11.2 Mitochondrial DNA depletion syndrome 9 (encephalomyopathic type with methylmalonic aciduria) AR 3 245400 SUCLG1 611224
3q29 ?Mitochondrial DNA depletion syndrome 14 (encephalocardiomyopathic type) AR 3 616896 OPA1 605290
4q35.1 Mitochondrial DNA depletion syndrome 12A (cardiomyopathic type) AD AD 3 617184 SLC25A4 103220
4q35.1 Mitochondrial DNA depletion syndrome 12B (cardiomyopathic type) AR AR 3 615418 SLC25A4 103220
6q16.1-q16.2 Mitochondrial DNA depletion syndrome 13 (encephalomyopathic type) AR 3 615471 FBXL4 605654
7p22.3 Mitochondrial DNA depletion syndrome 17 AR 3 618567 MRM2 606906
7q34 Sengers syndrome AR 3 212350 AGK 610345
8q22.3 Mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with renal tubulopathy) AR 3 612075 RRM2B 604712
8q22.3 Mitochondrial DNA depletion syndrome 8B (MNGIE type) AR 3 612075 RRM2B 604712
10q21.1 ?Mitochondrial DNA depletion syndrome 15 (hepatocerebral type) AR 3 617156 TFAM 600438
10q24.31 Mitochondrial DNA depletion syndrome 7 (hepatocerebral type) AR 3 271245 TWNK 606075
13q14.2 Mitochondrial DNA depletion syndrome 5 (encephalomyopathic with or without methylmalonic aciduria) AR 3 612073 SUCLA2 603921
14q13.3 ?Mitochondrial DNA depletion syndrome 18 AR 3 618811 SLC25A21 607571
15q26.1 Mitochondrial DNA depletion syndrome 4B (MNGIE type) AR 3 613662 POLG 174763
15q26.1 Mitochondrial DNA depletion syndrome 4A (Alpers type) AR 3 203700 POLG 174763
16q21 Mitochondrial DNA depletion syndrome 2 (myopathic type) AR 3 609560 TK2 188250
17q12 Mitochondrial DNA depletion syndrome 20 (MNGIE type) AR 3 619780 LIG3 600940
17q23.3 ?Mitochondrial DNA depletion syndrome 16B (neuroophthalmic type) AR 3 619425 POLG2 604983
17q23.3 ?Mitochondrial DNA depletion syndrome 16 (hepatic type) AR 3 618528 POLG2 604983
17q25.3 ?Mitochondrial DNA depletion syndrome 19 AR 3 618972 SLC25A10 606794
20p11.23 Mitochondrial DNA depletion syndrome 11 AR 3 615084 MGME1 615076
22q13.33 Mitochondrial DNA depletion syndrome 1 (MNGIE type) AR 3 603041 TYMP 131222

TEXT

A number sign (#) is used with this entry because mitochondrial DNA depletion syndrome-6 (MTDPS6), also known as Navajo neurohepatopathy (NNH), is caused by homozygous or compound heterozygous mutation in the MPV17 gene (137960) on chromosome 2p23.

Biallelic mutations in the MPV17 gene can also caused CMT2EE (618400), a much less severe disorder.


Description

Mitochondrial DNA depletion syndrome-6 is an autosomal recessive disorder characterized by infantile onset of progressive liver failure, often leading to death in the first year of life. Those that survive develop progressive neurologic involvement, including ataxia, hypotonia, dystonia, and psychomotor regression (Spinazzola et al., 2008).

For a discussion of genetic heterogeneity of autosomal recessive mtDNA depletion syndromes, see MTDPS1 (603041).


Clinical Features

Appenzeller et al. (1976) described 4 Navajo children with a mutilating neuropathy with severe motor involvement. The disorder appeared to be recessively inherited and was present from a very early age. Manifestations included severe anesthesia leading to corneal ulceration, painless fractures, and acral mutilation; muscle weakness; absent or markedly decreased deep tendon reflexes; and normal IQ. Sural nerve biopsy showed nearly complete absence of myelinated fibers without evidence of regeneration, and degenerative unmyelinated fibers with evidence of regeneration.

Snyder et al. (1988) reported 4 children with Navajo neuropathy, including 1 previously reported by Appenzeller et al. (1976), and extended the clinical spectrum to include progressive central nervous system white matter abnormalities with spinal cord atrophy in older children and onset during early infancy.

Singleton et al. (1990) performed a major epidemiologic survey of Navajo neuropathy, identifying 20 definite and 4 possible cases from a review of reservation hospital records and a questionnaire directed to all health providers on the Navajo reservation. The 24 cases identified came from 13 families, with 6 families having more than 1 affected child. Clinical features included sensorimotor neuropathy, corneal ulcerations, acral mutilation, poor weight gain, short stature, serious systemic infections, sexual infantilism, and liver disease. The liver disease presented as hepatomegaly, persistent neonatal jaundice, and even a Reye-like syndrome of acute hepatic failure. Brain imaging showed progressive CNS white matter lesions. Diagnosis was usually at the end of the first year of life or in the beginning of the second year, either because of neurologic symptoms or liver disease. The mean age of death was approximately 10 years, frequently due to liver disease. The incidence of this syndrome on the Western Navajo reservation was 5 times higher than on the Eastern reservations (38 compared to 7 cases per 100,000 births). Singleton et al. (1990) suggested an inborn error of metabolism, inherited in an autosomal recessive pattern.

In a review of 20 children with Navajo neuropathy, Holve et al. (1999) found that all had liver disease. Three phenotypes were observed, based on age at presentation and disease course: 5 patients had onset before 6 months of age with jaundice and failure to thrive followed by progression to liver failure before 2 years of age; 6 children had onset between 1 and 5 years of age with liver dysfunction progressing to liver failure and death within 6 months; and 9 children had variable onset of liver disease, but progressive neurologic deterioration. Liver histologic findings included multinucleated giant cells, macrovesicular and microvesicular steatosis, pseudo-acini, inflammation, cholestasis, and bridging fibrosis and cirrhosis. Cases of all 3 phenotypes occurred within the same kindred. Holve et al. (1999) emphasized that liver disease is an important component of Navajo neuropathy and may be the predominant feature in infants and young children. They proposed changing the name of the disorder to Navajo neurohepatopathy.

Erickson (1999) reviewed genetic diseases among the Navajo population.

Spinazzola et al. (2006) studied 3 families with the hepatocerebral form of mtDNA depletion syndrome caused by MPV17 mutations. In a multigeneration family originating from southern Italy, 2 children died of liver failure during the first year of life, but liver transplantation at 1 year of age in another child and dietary control of hypoglycemia in a fourth were effective in maintaining relative metabolic compensation and long-term survival. However, growth in the surviving children, who were 4 and 9 years old at the time of report, remained below the fifth percentile and the older child had developed neurologic symptoms and multiple brain lesions documented by MRI. The probands of the other 2 families died of liver failure in the first months after birth.

Spinazzola et al. (2008) reported 2 sisters, born of Iraqi consanguineous parents, with a hepatocerebral form of MTDPS confirmed by genetic analysis (137960.0005). The family history was positive for 2 miscarriages. At age 2 months, the older sister developed jaundice and hepatomegaly associated with clinical liver failure that progressed rapidly over the next few months. Initial MRI at age 3 months was normal but later showed edema of the white matter. She developed dystonic movements and deteriorating neurologic status and died from liver failure at age 11 months. The younger sister showed hypotonia and died of rapidly progressive liver failure at age 5 months. A third unrelated girl, conceived by artificial insemination because of a history of endometriosis in the mother, cried immediately after birth, fed poorly, and was jittery. At age 2 weeks, she was lethargic and had abnormal liver function tests. Brain MRI showed bilateral subdural hemorrhages with an area of periventricular leukomalacia in the right parietal region. Physical examination at age 5 months showed poor growth, hypotonia, roving eye movements, and nystagmus. She died of liver failure at 9 months of age. Genetic analysis showed compound heterozygosity for 2 mutations in the MPV17 gene (137960.0006; 137960.0007). Spinazzola et al. (2008) concluded that MPV17 mutations are associated with rapidly progressive infantile hepatic failure with subsequent neurologic involvement.

El-Hattab et al. (2018) reviewed 75 individuals with biallelic MPV17 mutations and added 25 newly described patients. The vast majority of patients presented with an early-onset encephalohepatic disease consistent with MTDPS6. Patients had failure to thrive, lactic acidemia, and mtDNA depletion, mainly in liver tissue. Hepatic abnormalities included elevated liver enzymes, jaundice, hyperbilirubinemia, cholestasis, steatosis, hepatomegaly, and frank liver failure. Neurologic abnormalities included hypotonia, developmental delay, and neurologic deterioration later in childhood. Common, but not universal, features included feeding difficulties, seizures, microcephaly, and sensorimotor peripheral neuropathy. Less common features (in less than 10% of patients) included dystonia, ataxia, retinopathy, corneal ulcerations, nystagmus, renal tubulopathy, nephrocalcinosis, and hypoparathyroidism. Brain imaging showed diffuse white matter abnormalities consistent with leukodystrophy or hypomyelination, but many had normal scans. The prognosis was very poor: most patients (about 75%) died in the first decade of liver or multiorgan failure. Four of the 100 patients presented with later onset of a neuromyopathic disease with little or no liver involvement (see CMT2EE; 618400).

Navajo Familial Neurogenic Arthropathy

Johnsen et al. (1993) reported 8 Navajo children with a disorder that they termed 'Navajo familial neurogenic arthropathy,' which was characterized by Charcot joints (neurogenic arthropathy) and unrecognized fractures, but with intact reflexes and normal strength. The sensory examination was variable: many had no discernible sensory deficit, whereas others had subtle deficiency in deep pain sensation, temperature discrimination, and corneal sensitivity. Nerve conduction velocities were normal, but sural nerve biopsy showed a marked reduction in small myelinated and unmyelinated nerve fibers. The 8 patients were distributed in 3 families in a pattern consistent with autosomal recessive inheritance. Johnsen et al. (1993) concluded that the disorder was distinct from that described by Appenzeller et al. (1976) as an acromutilating sensory neuropathy.


Diagnosis

Confounding Phenotypes

Ebermann et al. (2008) reported an 11-year-old boy, born of Egyptian consanguineous parents, with a phenotype suggestive of Navajo neurohepatopathy, including short stature, frequent painless fractures, bruises, and cuts, hepatomegaly with elevated liver enzymes, corneal ulcerations, and mild hypotonia. His 22-month-old sister had short stature, hepatomegaly, increased liver enzymes, and hypotonia. A cousin had died at age 8 years from liver failure. After genetic analysis excluded a mutation in the MPV17 gene, Ebermann et al. (2008) postulated 2 recessive diseases. Genomewide linkage analysis and gene sequencing of the proband identified a homozygous mutation in the AGL gene (610860), consistent with glycogen storage disease III (GSD3; 232400), and a homozygous mutation in the SCN9A gene (603415), consistent with congenital insensitivity to pain (CIPA; 243000). His sister had the AGL mutation and GSD3 only. Ebermann et al. (2008) emphasized that consanguineous matings increase the risk of homozygous genotypes and recessive diseases, which may complicate genetic counseling.


Mapping

The clinical, pathologic, and biochemical features seen in patients with NNH resembles those in patients with mtDNA depletion syndrome, suggesting that abnormal regulation of mtDNA copy number may be the primary defect in NNH (Vu et al., 2001). Homozygosity mapping of 2 families with NNH suggested linkage to chromosome 2p24 (Karadimas et al., 2006). This locus includes the MPV17 gene, which, when mutated, was known to cause hepatocerebral mtDNA depletion syndrome.


Inheritance

The transmission pattern of MTDPS6 in the families reported by Spinazzola et al. (2006) was consistent with autosomal recessive inheritance.


Molecular Genetics

In affected members of an Italian and Moroccan family with the hepatocerebral form of mtDNA depletion syndrome, Spinazzola et al. (2006) identified homozygous mutations in the MPV17 gene (137960.0001-137960.0002). An affected proband from a Canadian family was found to be compound heterozygous for 2 MPV17 mutations (137960.0003 and 137960.0004).

Karadimas et al. (2006) sequenced the MPV17 gene in 6 patients with Navajo neurohepatopathy from 5 families and found the homozygous arg50-to-gln mutation previously described in a southern Italian family (137960.0001) with hepatocerebral mtDNA depletion syndrome (Spinazzola et al., 2006). Identification of a single missense mutation in patients with NNH confirmed that the disease is probably due to a founder effect, and extended the phenotypic spectrum associated with MPV17 mutations.


Genotype/Phenotype Correlations

In a large review of 100 patients, El-Hattab et al. (2018) found that about half of the pathogenic MPV17 variants were missense, but other types of mutations (nonsense, frameshift, in-frame deletions, splice site) occurred throughout the gene. In general, those with biallelic missense mutations tended to have a less severe phenotype, in particular those with homozygous R50Q (137960.0001), P98L (137960.0008), or R41Q (137960.0009) mutations.


Animal Model

In an Mpv17-knockout mouse model, Viscomi et al. (2009) found severe mtDNA depletion in liver and skeletal muscle, whereas hardly any depletion was detected in brain and kidney. Mouse embryonic fibroblasts only showed mtDNA depletion after several culturing passages or in serum-free medium. In spite of severe mtDNA depletion, only moderate decreases in respiratory chain enzymatic activities and mild cytoarchitectural alterations were observed in Mpv17 -/- livers, but neither cirrhosis nor failure ever occurred. The mtDNA transcription rate was markedly increased in liver, which could contribute to compensation for the severe mtDNA depletion. This phenomenon was associated with specific downregulation of Mterf (602318), a negative modulator of mtDNA transcription. The most relevant clinical features involved skin, inner ear, and kidney. The coat of the Mpv17 -/- mice turned gray early in adulthood, and 18-month or older mice developed focal segmental glomerulosclerosis (FSGS) with massive proteinuria. Concomitant degeneration of cochlear sensory epithelia was reported as well. These symptoms were associated with significantly shorter life span. Coincidental with the onset of FSGS, minimal mtDNA was measurable in glomerular tufts.


REFERENCES

  1. Appenzeller, O., Kornfeld, M., Snyder, R. Acromutilating, paralyzing neuropathy with corneal ulceration in Navajo children. Arch. Neurol. 33: 733-738, 1976. [PubMed: 185990, related citations] [Full Text]

  2. Ebermann, I., Elsayed, S. M., Abdel-Ghaffar, T. Y., Nurnberg, G., Nurnberg, P., Elsobky, E., Bolz, H. J. Double homozygosity for mutations of AGL and SCN9A mimicking neurohepatopathy syndrome. Neurology 70: 2343-2344, 2008. [PubMed: 18541889, related citations] [Full Text]

  3. El-Hattab, A. W., Wang, J., Dai, H., Almannai, M., Staufner, C., Alfadhel, M., Gambello, M. J., Prasun, P., Raza, S., Lyons, H. J., Afqi, M., Saleh, M. A. M., and 11 others. MPV17-related mitochondrial DNA maintenance defect: new cases and review of clinical, biochemical, and molecular aspects. Hum. Mutat. 39: 461-40, 2018. [PubMed: 29282788, related citations] [Full Text]

  4. Erickson, R. P. Southwestern Athabaskan (Navajo and Apache) genetic diseases. Genet. Med. 1: 151-157, 1999. [PubMed: 11258351, related citations] [Full Text]

  5. Holve, S., Hu, D., Shub, M., Tyson, R. W., Sokol, R. J. Liver disease in Navajo neuropathy. J. Pediat. 135: 482-493, 1999. [PubMed: 10518083, related citations] [Full Text]

  6. Johnsen, S. D., Johnson, P. C., Stein, S. R. Familial sensory autonomic neuropathy with arthropathy in Navajo children. Neurology 43: 1120-1125, 1993. [PubMed: 8170555, related citations] [Full Text]

  7. Karadimas, C. L., Vu, T. H., Holve, S. A., Chronopoulou, P., Quinzii, C., Johnsen, S. D., Kurth, J., Eggers, E., Palenzuela, L., Tanji, K., Bonilla, E., De Vivo, D. C., DiMauro, S., Hitano, M. Navajo neurohepatopathy is caused by a mutation in the MPV17 gene. Am. J. Hum. Genet. 79: 544-548, 2006. [PubMed: 16909392, related citations] [Full Text]

  8. Singleton, R., Helgerson, S. D., Snyder, R. D., O'Conner, P. J., Nelson, S., Johnsen, S. D., Allanson, J. E. Neuropathy in Navajo children: clinical and epidemiologic features. Neurology 40: 363-367, 1990. [PubMed: 2300261, related citations] [Full Text]

  9. Snyder, R. D., Appenzeller, O., Johnson, P. C., Ferry, P. C., Capin, D. M., Singleton, R., Johnsen, S. D., Orrison, W. Infantile onset and late central white matter lesions in Navajo neuropathy. (Abstract) Ann. Neurol. 24: 327 only, 1988.

  10. Spinazzola, A., Santer, R., Akman, O. H., Tsiakas, K., Schaefer, H., Ding, X., Karadimas, C. L., Shanske, S., Ganesh, J., Di Mauro, S., Zeviani, M. Hepatocerebral form of mitochondrial DNA depletion syndrome: novel MPV17 mutations. Arch. Neurol. 65: 1108-1113, 2008. [PubMed: 18695062, related citations] [Full Text]

  11. Spinazzola, A., Viscomi, C., Fernandez-Vizarra, E., Carrara, F., D'Adamo, P., Calvo, S., Marsano, R. M., Donnini, C., Weiher, H., Strisciuglio, P., Parini, R., Sarzi, E., Chan, A., DiMauro, S., Rotig, A., Gasparini, P., Ferrero, I., Mootha, V. K., Tiranti, V., Zeviani, M. MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. Nature Genet. 38: 570-575, 2006. [PubMed: 16582910, related citations] [Full Text]

  12. Viscomi, C., Spinazzola, A., Maggioni, M., Fernandez-Vizarra, E., Massa, V., Pagano, C., Vettor, R., Mora, M., Zeviani, M. Early-onset liver mtDNA depletion and late-onset proteinuric nephropathy in Mpv17 knockout mice. Hum. Molec. Genet. 18: 12-26, 2009. [PubMed: 18818194, images, related citations] [Full Text]

  13. Vu, T. H., Tanji, K., Holve, S. A., Bonilla, E., Sokol, R. J., Snyder, R. D., Fiore, S., Deutsch, G. H., DiMauro, S., De Vivo, D. Navajo neurohepatopathy: a mitochondrial DNA depletion syndrome? Hepatology 34: 116-120, 2001. [PubMed: 11431741, related citations] [Full Text]


Cassandra L. Kniffin - updated : 04/24/2019
Cassandra L. Kniffin - updated : 12/9/2010
Cassandra L. Kniffin - updated : 10/8/2008
Victor A. McKusick - updated : 8/23/2006
Cassandra L. Kniffin - reorganized : 5/24/2004
Cassandra L. Kniffin - updated : 5/17/2004
Victor A. McKusick - updated : 9/15/1999
Creation Date:
Victor A. McKusick : 8/28/1987
carol : 12/10/2024
carol : 05/14/2019
alopez : 04/25/2019
ckniffin : 04/24/2019
carol : 06/10/2016
carol : 6/8/2016
carol : 10/16/2012
carol : 12/21/2010
carol : 12/20/2010
ckniffin : 12/9/2010
wwang : 10/15/2008
ckniffin : 10/8/2008
alopez : 8/25/2006
terry : 8/23/2006
carol : 5/24/2004
ckniffin : 5/17/2004
joanna : 3/19/2004
carol : 9/20/1999
mgross : 9/20/1999
terry : 9/15/1999
mimadm : 3/11/1994
carol : 9/8/1993
supermim : 3/17/1992
supermim : 3/20/1990
ddp : 10/27/1989
marie : 3/25/1988

# 256810

MITOCHONDRIAL DNA DEPLETION SYNDROME 6 (HEPATOCEREBRAL TYPE); MTDPS6


Alternative titles; symbols

NAVAJO NEUROHEPATOPATHY; NNH
NAVAJO NEUROPATHY; NN


Other entities represented in this entry:

NAVAJO FAMILIAL NEUROGENIC ARTHROPATHY, INCLUDED

SNOMEDCT: 784346006;   ORPHA: 255229;   DO: 0080125;  


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
2p23.3 Mitochondrial DNA depletion syndrome 6 (hepatocerebral type) 256810 Autosomal recessive 3 MPV17 137960

TEXT

A number sign (#) is used with this entry because mitochondrial DNA depletion syndrome-6 (MTDPS6), also known as Navajo neurohepatopathy (NNH), is caused by homozygous or compound heterozygous mutation in the MPV17 gene (137960) on chromosome 2p23.

Biallelic mutations in the MPV17 gene can also caused CMT2EE (618400), a much less severe disorder.


Description

Mitochondrial DNA depletion syndrome-6 is an autosomal recessive disorder characterized by infantile onset of progressive liver failure, often leading to death in the first year of life. Those that survive develop progressive neurologic involvement, including ataxia, hypotonia, dystonia, and psychomotor regression (Spinazzola et al., 2008).

For a discussion of genetic heterogeneity of autosomal recessive mtDNA depletion syndromes, see MTDPS1 (603041).


Clinical Features

Appenzeller et al. (1976) described 4 Navajo children with a mutilating neuropathy with severe motor involvement. The disorder appeared to be recessively inherited and was present from a very early age. Manifestations included severe anesthesia leading to corneal ulceration, painless fractures, and acral mutilation; muscle weakness; absent or markedly decreased deep tendon reflexes; and normal IQ. Sural nerve biopsy showed nearly complete absence of myelinated fibers without evidence of regeneration, and degenerative unmyelinated fibers with evidence of regeneration.

Snyder et al. (1988) reported 4 children with Navajo neuropathy, including 1 previously reported by Appenzeller et al. (1976), and extended the clinical spectrum to include progressive central nervous system white matter abnormalities with spinal cord atrophy in older children and onset during early infancy.

Singleton et al. (1990) performed a major epidemiologic survey of Navajo neuropathy, identifying 20 definite and 4 possible cases from a review of reservation hospital records and a questionnaire directed to all health providers on the Navajo reservation. The 24 cases identified came from 13 families, with 6 families having more than 1 affected child. Clinical features included sensorimotor neuropathy, corneal ulcerations, acral mutilation, poor weight gain, short stature, serious systemic infections, sexual infantilism, and liver disease. The liver disease presented as hepatomegaly, persistent neonatal jaundice, and even a Reye-like syndrome of acute hepatic failure. Brain imaging showed progressive CNS white matter lesions. Diagnosis was usually at the end of the first year of life or in the beginning of the second year, either because of neurologic symptoms or liver disease. The mean age of death was approximately 10 years, frequently due to liver disease. The incidence of this syndrome on the Western Navajo reservation was 5 times higher than on the Eastern reservations (38 compared to 7 cases per 100,000 births). Singleton et al. (1990) suggested an inborn error of metabolism, inherited in an autosomal recessive pattern.

In a review of 20 children with Navajo neuropathy, Holve et al. (1999) found that all had liver disease. Three phenotypes were observed, based on age at presentation and disease course: 5 patients had onset before 6 months of age with jaundice and failure to thrive followed by progression to liver failure before 2 years of age; 6 children had onset between 1 and 5 years of age with liver dysfunction progressing to liver failure and death within 6 months; and 9 children had variable onset of liver disease, but progressive neurologic deterioration. Liver histologic findings included multinucleated giant cells, macrovesicular and microvesicular steatosis, pseudo-acini, inflammation, cholestasis, and bridging fibrosis and cirrhosis. Cases of all 3 phenotypes occurred within the same kindred. Holve et al. (1999) emphasized that liver disease is an important component of Navajo neuropathy and may be the predominant feature in infants and young children. They proposed changing the name of the disorder to Navajo neurohepatopathy.

Erickson (1999) reviewed genetic diseases among the Navajo population.

Spinazzola et al. (2006) studied 3 families with the hepatocerebral form of mtDNA depletion syndrome caused by MPV17 mutations. In a multigeneration family originating from southern Italy, 2 children died of liver failure during the first year of life, but liver transplantation at 1 year of age in another child and dietary control of hypoglycemia in a fourth were effective in maintaining relative metabolic compensation and long-term survival. However, growth in the surviving children, who were 4 and 9 years old at the time of report, remained below the fifth percentile and the older child had developed neurologic symptoms and multiple brain lesions documented by MRI. The probands of the other 2 families died of liver failure in the first months after birth.

Spinazzola et al. (2008) reported 2 sisters, born of Iraqi consanguineous parents, with a hepatocerebral form of MTDPS confirmed by genetic analysis (137960.0005). The family history was positive for 2 miscarriages. At age 2 months, the older sister developed jaundice and hepatomegaly associated with clinical liver failure that progressed rapidly over the next few months. Initial MRI at age 3 months was normal but later showed edema of the white matter. She developed dystonic movements and deteriorating neurologic status and died from liver failure at age 11 months. The younger sister showed hypotonia and died of rapidly progressive liver failure at age 5 months. A third unrelated girl, conceived by artificial insemination because of a history of endometriosis in the mother, cried immediately after birth, fed poorly, and was jittery. At age 2 weeks, she was lethargic and had abnormal liver function tests. Brain MRI showed bilateral subdural hemorrhages with an area of periventricular leukomalacia in the right parietal region. Physical examination at age 5 months showed poor growth, hypotonia, roving eye movements, and nystagmus. She died of liver failure at 9 months of age. Genetic analysis showed compound heterozygosity for 2 mutations in the MPV17 gene (137960.0006; 137960.0007). Spinazzola et al. (2008) concluded that MPV17 mutations are associated with rapidly progressive infantile hepatic failure with subsequent neurologic involvement.

El-Hattab et al. (2018) reviewed 75 individuals with biallelic MPV17 mutations and added 25 newly described patients. The vast majority of patients presented with an early-onset encephalohepatic disease consistent with MTDPS6. Patients had failure to thrive, lactic acidemia, and mtDNA depletion, mainly in liver tissue. Hepatic abnormalities included elevated liver enzymes, jaundice, hyperbilirubinemia, cholestasis, steatosis, hepatomegaly, and frank liver failure. Neurologic abnormalities included hypotonia, developmental delay, and neurologic deterioration later in childhood. Common, but not universal, features included feeding difficulties, seizures, microcephaly, and sensorimotor peripheral neuropathy. Less common features (in less than 10% of patients) included dystonia, ataxia, retinopathy, corneal ulcerations, nystagmus, renal tubulopathy, nephrocalcinosis, and hypoparathyroidism. Brain imaging showed diffuse white matter abnormalities consistent with leukodystrophy or hypomyelination, but many had normal scans. The prognosis was very poor: most patients (about 75%) died in the first decade of liver or multiorgan failure. Four of the 100 patients presented with later onset of a neuromyopathic disease with little or no liver involvement (see CMT2EE; 618400).

Navajo Familial Neurogenic Arthropathy

Johnsen et al. (1993) reported 8 Navajo children with a disorder that they termed 'Navajo familial neurogenic arthropathy,' which was characterized by Charcot joints (neurogenic arthropathy) and unrecognized fractures, but with intact reflexes and normal strength. The sensory examination was variable: many had no discernible sensory deficit, whereas others had subtle deficiency in deep pain sensation, temperature discrimination, and corneal sensitivity. Nerve conduction velocities were normal, but sural nerve biopsy showed a marked reduction in small myelinated and unmyelinated nerve fibers. The 8 patients were distributed in 3 families in a pattern consistent with autosomal recessive inheritance. Johnsen et al. (1993) concluded that the disorder was distinct from that described by Appenzeller et al. (1976) as an acromutilating sensory neuropathy.


Diagnosis

Confounding Phenotypes

Ebermann et al. (2008) reported an 11-year-old boy, born of Egyptian consanguineous parents, with a phenotype suggestive of Navajo neurohepatopathy, including short stature, frequent painless fractures, bruises, and cuts, hepatomegaly with elevated liver enzymes, corneal ulcerations, and mild hypotonia. His 22-month-old sister had short stature, hepatomegaly, increased liver enzymes, and hypotonia. A cousin had died at age 8 years from liver failure. After genetic analysis excluded a mutation in the MPV17 gene, Ebermann et al. (2008) postulated 2 recessive diseases. Genomewide linkage analysis and gene sequencing of the proband identified a homozygous mutation in the AGL gene (610860), consistent with glycogen storage disease III (GSD3; 232400), and a homozygous mutation in the SCN9A gene (603415), consistent with congenital insensitivity to pain (CIPA; 243000). His sister had the AGL mutation and GSD3 only. Ebermann et al. (2008) emphasized that consanguineous matings increase the risk of homozygous genotypes and recessive diseases, which may complicate genetic counseling.


Mapping

The clinical, pathologic, and biochemical features seen in patients with NNH resembles those in patients with mtDNA depletion syndrome, suggesting that abnormal regulation of mtDNA copy number may be the primary defect in NNH (Vu et al., 2001). Homozygosity mapping of 2 families with NNH suggested linkage to chromosome 2p24 (Karadimas et al., 2006). This locus includes the MPV17 gene, which, when mutated, was known to cause hepatocerebral mtDNA depletion syndrome.


Inheritance

The transmission pattern of MTDPS6 in the families reported by Spinazzola et al. (2006) was consistent with autosomal recessive inheritance.


Molecular Genetics

In affected members of an Italian and Moroccan family with the hepatocerebral form of mtDNA depletion syndrome, Spinazzola et al. (2006) identified homozygous mutations in the MPV17 gene (137960.0001-137960.0002). An affected proband from a Canadian family was found to be compound heterozygous for 2 MPV17 mutations (137960.0003 and 137960.0004).

Karadimas et al. (2006) sequenced the MPV17 gene in 6 patients with Navajo neurohepatopathy from 5 families and found the homozygous arg50-to-gln mutation previously described in a southern Italian family (137960.0001) with hepatocerebral mtDNA depletion syndrome (Spinazzola et al., 2006). Identification of a single missense mutation in patients with NNH confirmed that the disease is probably due to a founder effect, and extended the phenotypic spectrum associated with MPV17 mutations.


Genotype/Phenotype Correlations

In a large review of 100 patients, El-Hattab et al. (2018) found that about half of the pathogenic MPV17 variants were missense, but other types of mutations (nonsense, frameshift, in-frame deletions, splice site) occurred throughout the gene. In general, those with biallelic missense mutations tended to have a less severe phenotype, in particular those with homozygous R50Q (137960.0001), P98L (137960.0008), or R41Q (137960.0009) mutations.


Animal Model

In an Mpv17-knockout mouse model, Viscomi et al. (2009) found severe mtDNA depletion in liver and skeletal muscle, whereas hardly any depletion was detected in brain and kidney. Mouse embryonic fibroblasts only showed mtDNA depletion after several culturing passages or in serum-free medium. In spite of severe mtDNA depletion, only moderate decreases in respiratory chain enzymatic activities and mild cytoarchitectural alterations were observed in Mpv17 -/- livers, but neither cirrhosis nor failure ever occurred. The mtDNA transcription rate was markedly increased in liver, which could contribute to compensation for the severe mtDNA depletion. This phenomenon was associated with specific downregulation of Mterf (602318), a negative modulator of mtDNA transcription. The most relevant clinical features involved skin, inner ear, and kidney. The coat of the Mpv17 -/- mice turned gray early in adulthood, and 18-month or older mice developed focal segmental glomerulosclerosis (FSGS) with massive proteinuria. Concomitant degeneration of cochlear sensory epithelia was reported as well. These symptoms were associated with significantly shorter life span. Coincidental with the onset of FSGS, minimal mtDNA was measurable in glomerular tufts.


REFERENCES

  1. Appenzeller, O., Kornfeld, M., Snyder, R. Acromutilating, paralyzing neuropathy with corneal ulceration in Navajo children. Arch. Neurol. 33: 733-738, 1976. [PubMed: 185990] [Full Text: https://doi.org/10.1001/archneur.1976.00500110001001]

  2. Ebermann, I., Elsayed, S. M., Abdel-Ghaffar, T. Y., Nurnberg, G., Nurnberg, P., Elsobky, E., Bolz, H. J. Double homozygosity for mutations of AGL and SCN9A mimicking neurohepatopathy syndrome. Neurology 70: 2343-2344, 2008. [PubMed: 18541889] [Full Text: https://doi.org/10.1212/01.wnl.0000314731.65875.5c]

  3. El-Hattab, A. W., Wang, J., Dai, H., Almannai, M., Staufner, C., Alfadhel, M., Gambello, M. J., Prasun, P., Raza, S., Lyons, H. J., Afqi, M., Saleh, M. A. M., and 11 others. MPV17-related mitochondrial DNA maintenance defect: new cases and review of clinical, biochemical, and molecular aspects. Hum. Mutat. 39: 461-40, 2018. [PubMed: 29282788] [Full Text: https://doi.org/10.1002/humu.23387]

  4. Erickson, R. P. Southwestern Athabaskan (Navajo and Apache) genetic diseases. Genet. Med. 1: 151-157, 1999. [PubMed: 11258351] [Full Text: https://doi.org/10.1097/00125817-199905000-00007]

  5. Holve, S., Hu, D., Shub, M., Tyson, R. W., Sokol, R. J. Liver disease in Navajo neuropathy. J. Pediat. 135: 482-493, 1999. [PubMed: 10518083] [Full Text: https://doi.org/10.1016/s0022-3476(99)70172-1]

  6. Johnsen, S. D., Johnson, P. C., Stein, S. R. Familial sensory autonomic neuropathy with arthropathy in Navajo children. Neurology 43: 1120-1125, 1993. [PubMed: 8170555] [Full Text: https://doi.org/10.1212/wnl.43.6.1120]

  7. Karadimas, C. L., Vu, T. H., Holve, S. A., Chronopoulou, P., Quinzii, C., Johnsen, S. D., Kurth, J., Eggers, E., Palenzuela, L., Tanji, K., Bonilla, E., De Vivo, D. C., DiMauro, S., Hitano, M. Navajo neurohepatopathy is caused by a mutation in the MPV17 gene. Am. J. Hum. Genet. 79: 544-548, 2006. [PubMed: 16909392] [Full Text: https://doi.org/10.1086/506913]

  8. Singleton, R., Helgerson, S. D., Snyder, R. D., O'Conner, P. J., Nelson, S., Johnsen, S. D., Allanson, J. E. Neuropathy in Navajo children: clinical and epidemiologic features. Neurology 40: 363-367, 1990. [PubMed: 2300261] [Full Text: https://doi.org/10.1212/wnl.40.2.363]

  9. Snyder, R. D., Appenzeller, O., Johnson, P. C., Ferry, P. C., Capin, D. M., Singleton, R., Johnsen, S. D., Orrison, W. Infantile onset and late central white matter lesions in Navajo neuropathy. (Abstract) Ann. Neurol. 24: 327 only, 1988.

  10. Spinazzola, A., Santer, R., Akman, O. H., Tsiakas, K., Schaefer, H., Ding, X., Karadimas, C. L., Shanske, S., Ganesh, J., Di Mauro, S., Zeviani, M. Hepatocerebral form of mitochondrial DNA depletion syndrome: novel MPV17 mutations. Arch. Neurol. 65: 1108-1113, 2008. [PubMed: 18695062] [Full Text: https://doi.org/10.1001/archneur.65.8.1108]

  11. Spinazzola, A., Viscomi, C., Fernandez-Vizarra, E., Carrara, F., D'Adamo, P., Calvo, S., Marsano, R. M., Donnini, C., Weiher, H., Strisciuglio, P., Parini, R., Sarzi, E., Chan, A., DiMauro, S., Rotig, A., Gasparini, P., Ferrero, I., Mootha, V. K., Tiranti, V., Zeviani, M. MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. Nature Genet. 38: 570-575, 2006. [PubMed: 16582910] [Full Text: https://doi.org/10.1038/ng1765]

  12. Viscomi, C., Spinazzola, A., Maggioni, M., Fernandez-Vizarra, E., Massa, V., Pagano, C., Vettor, R., Mora, M., Zeviani, M. Early-onset liver mtDNA depletion and late-onset proteinuric nephropathy in Mpv17 knockout mice. Hum. Molec. Genet. 18: 12-26, 2009. [PubMed: 18818194] [Full Text: https://doi.org/10.1093/hmg/ddn309]

  13. Vu, T. H., Tanji, K., Holve, S. A., Bonilla, E., Sokol, R. J., Snyder, R. D., Fiore, S., Deutsch, G. H., DiMauro, S., De Vivo, D. Navajo neurohepatopathy: a mitochondrial DNA depletion syndrome? Hepatology 34: 116-120, 2001. [PubMed: 11431741] [Full Text: https://doi.org/10.1053/jhep.2001.25921]


Contributors:
Cassandra L. Kniffin - updated : 04/24/2019
Cassandra L. Kniffin - updated : 12/9/2010
Cassandra L. Kniffin - updated : 10/8/2008
Victor A. McKusick - updated : 8/23/2006
Cassandra L. Kniffin - reorganized : 5/24/2004
Cassandra L. Kniffin - updated : 5/17/2004
Victor A. McKusick - updated : 9/15/1999

Creation Date:
Victor A. McKusick : 8/28/1987

Edit History:
carol : 12/10/2024
carol : 05/14/2019
alopez : 04/25/2019
ckniffin : 04/24/2019
carol : 06/10/2016
carol : 6/8/2016
carol : 10/16/2012
carol : 12/21/2010
carol : 12/20/2010
ckniffin : 12/9/2010
wwang : 10/15/2008
ckniffin : 10/8/2008
alopez : 8/25/2006
terry : 8/23/2006
carol : 5/24/2004
ckniffin : 5/17/2004
joanna : 3/19/2004
carol : 9/20/1999
mgross : 9/20/1999
terry : 9/15/1999
mimadm : 3/11/1994
carol : 9/8/1993
supermim : 3/17/1992
supermim : 3/20/1990
ddp : 10/27/1989
marie : 3/25/1988